Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for United Therapeutics Corporation (UTHR : NSDQ)

• Company Description    United Therapeutics Corporation markets four medicines in the United States to treat pulmonary arterial hypertension (PAH): Remodulin, an injectable formulation of treprostinil, Orenitram, an oral version of treprostinil, Tyvaso, an inhaled version of treprostinil, and Adcirca (tadalafil; also sold by Eli Lilly as Cialis for erectile dysfunction) tablets. Number of Employees: 1,400

• Price / Volume Information    Yesterday's Closing Price: $503.90 Daily Weekly Monthly 20 Day Moving Average: 358,087 shares Shares Outstanding: 43.83 (millions) Market Capitalization: $22,084.77 (millions) Beta: 0.84 52 Week High: $537.19 52 Week Low: $266.98 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 7.33% 8.27% 12 Week 2.98% 2.85% Year To Date 3.42% 2.92%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1000 SPRING ST - SILVER SPRING,MD 20910 USA ph: 301-608-9292 fax: 301-608-9291 ir@unither.com http://www.unither.com

• General Corporate Information    Officers Martine Rothblatt - Chairperson and Chief Executive Officer Michael Benkowitz - President and Chief Operating Officer James C. Edgemond - Chief Financial Officer and Treasurer Paul A. Mahon - Executive Vice President; General Counsel; and Cor Christopher Causey - Director Peer Information United Therapeutics Corporation (GSAC) United Therapeutics Corporation (CASIF) United Therapeutics Corporation (ALCD.) United Therapeutics Corporation (OMNN) United Therapeutics Corporation (CGPI.) United Therapeutics Corporation (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 91307C102 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/25 Next Expected EPS Date: 04/29/26 Share - Related Items Shares Outstanding: 43.83 Most Recent Split Date: 9.00 (2.00:1) Beta: 0.84 Market Capitalization: $22,084.77 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $6.73 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $27.94 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: 0.00 Estmated Long-Term EPS Growth Rate: 10.14% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 04/29/26

• Fundamental Ratios P/E Current FY Estimate: 18.03 Trailing 12 Months: 18.06 PEG Ratio: 1.78 Price Ratios Price/Book: 3.06 Price/Cash Flow: 15.28 Price / Sales: 6.94 EPS Growth vs. Year Ago Period: 24.39% vs. Previous Quarter: 7.54% Sales Growth vs. Year Ago Period: 7.38% vs. Previous Quarter: -1.16% ROE 12/31/25 - 19.30 09/30/25 - 18.83 06/30/25 - 18.73 ROA 12/31/25 - 17.29 09/30/25 - 16.75 06/30/25 - 16.49 Current Ratio 12/31/25 - 6.60 09/30/25 - 6.40 06/30/25 - 7.26 Quick Ratio 12/31/25 - 6.28 09/30/25 - 6.07 06/30/25 - 6.94 Operating Margin 12/31/25 - 41.94 09/30/25 - 40.65 06/30/25 - 40.36 Net Margin 12/31/25 - 41.94 09/30/25 - 40.65 06/30/25 - 40.36 Pre-Tax Margin 12/31/25 - 53.85 09/30/25 - 53.27 06/30/25 - 52.54 Book Value 12/31/25 - 164.81 09/30/25 - 153.06 06/30/25 - 159.04 Inventory Turnover 12/31/25 - 2.21 09/30/25 - 2.13 06/30/25 - 2.12 Debt-to-Equity 12/31/25 - 0.00 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - 0.00 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©